Where Science Meets Technology by Appsilon is a series of interviews and discussions focused on how technology can accelerate data science processes, particularly within life sciences and biopharmaceutical companies.
Each episode will explore various aspects of innovation and its potential to address challenges where traditional methods may fall short. We will feature internal experts from our delivery teams, along with clients and partners as guest speakers, providing valuable insights into the intersection of science and technology.
The podcast is brought to you by Appsilon.
Appsilon empowers Fortune 500 companies to leverage open-source technology for faster, data-driven decision-making in regulated environments
#010 Centralized Monitoring: Risk-based Approach to Clinical Trial Processes
#006 Inside Novo Nordisk’s Path to Open Source for the Pharma and Beyond
Published:
Ari Siggaard Knoph from Novo Nordisk shares how the company transitioned from SAS to R for FDA submissions. From early Shiny apps to full-scale open-source workflows, learn how this shift accelerated innovation, attracted top talent, and redefined clinical programming.
#005 Shiny’s Evolution: From Prototyping Tool to Critical Technology in Pharma
#2 Pharma Brief: AI’s Impact on Clinical Trials, Must-See Open Source Tools, and Upcoming Pharma Events
Published:
Pharma Brief is back with the latest edition, packed with valuable insights and upcoming events you don’t want to miss. This month, we’re exploring AI’s impact on clinical development (trials could be 30% faster!), along with innovative tools that streamline processes. We’ve also highlighted open-source packages to optimize your workflows.
#004 Technology Transformation in Clinical Trial Analysis
#1 Pharma Brief: J&J Moves to Open Source, AI-powered Data Extraction, and Top Clinical Trials for 2025
Published:
Pharma Brief delivers your monthly pulse on pharma’s evolving landscape. Stay ahead with curated insights on FDA/EMA updates, AI-driven trends, and must-attend global events. We unpack breakthroughs—from novel drug approvals to open-source tools like R/Shiny—and arm you with actionable resources to in tech transformations in clinical trials. Whether it’s GxP compliance strategies or clinico-genomic advancements, we’re here to sharpen your expertise.
#003 The Future of GxP Compliance in Pharma: R-based Submissions
#002 How NASA Chooses the Right Talent for Space Exploration
Published:
In this episode of Technology Meets Science, we welcome David Meza, Head of Analytics at NASA’s Human Capital Office. David shares how data science and AI are transforming talent management at NASA, ensuring the right individuals are matched with critical missions. From knowledge graphs to generative AI, he explains how NASA is leveraging technology to optimize workforce planning, upskilling, and recruitment. Tune in for insights on AI-driven talent analytics, the challenges of data accessibility, and what it takes to land a career at NASA.
#001 Why Clinical Trials Fail: Lessons from Two Decades in Pharma
Published:
Together with Eric Genevois-Marlin, former Head of Data Sciences in R&D and Biostatistics at Sanofi, we uncover the reasons behind clinical trial failures. Drawing from his 20+ years of experience leading science and technology teams in bringing new drugs to market, we'll examine real-world examples and extract lessons from both successes and failures.In this episode, you will learn:
#000 Where Technology Meets Science by Appsilon Trailer
Published:
"Where Technology Meets Science" is a podcast series diving into the intersection of technology and life sciences. We bring together industry experts, innovators, and thought leaders to explore how advanced technologies are reshaping data science processes in biotechnology, biopharma, environmental sciences, genetics, and similar fields. Together with experts from companies like Roche, Novartis, NASA, and J&J, we uncover solutions that address complex challenges, accelerate research, and push beyond traditional scientific methods, offering listeners insights into the evolving landscape of scientific discovery.